Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ce |
RCV000416186 | SCV000493569 | uncertain significance | not provided | 2016-07-01 | criteria provided, single submitter | clinical testing | |
| Illumina Laboratory Services, |
RCV000779394 | SCV000916001 | uncertain significance | Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 | 2017-10-20 | criteria provided, single submitter | clinical testing | The GFM1 c.829dupT (p.Ser277PhefsTer2) variant results in a frameshift and is predicted to result in premature termination of the protein. It was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018) and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score for this variant, it could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene and cDNA change, and amino acid change. No publications were found based on this search. Due to the potential impact of frameshift variants and the lack of clarifying evidence, this variant is classified as a variant of unknown significance but suspicious for pathogenicity for combined oxidative phosphorylation deficiency. |
| Centre for Mendelian Genomics, |
RCV000779394 | SCV001370333 | likely pathogenic | Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 | 2019-08-29 | criteria provided, single submitter | clinical testing | This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2. |
| Labcorp Genetics |
RCV000416186 | SCV001375568 | pathogenic | not provided | 2023-10-13 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser277Phefs*2) in the GFM1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GFM1 are known to be pathogenic (PMID: 16632485, 17160893). This variant is present in population databases (rs771865940, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with GFM1-related conditions. ClinVar contains an entry for this variant (Variation ID: 374695). For these reasons, this variant has been classified as Pathogenic. |
| Baylor Genetics | RCV000779394 | SCV004199306 | likely pathogenic | Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 | 2024-03-26 | criteria provided, single submitter | clinical testing |